The prestigious Johns Hopkins University Center for Psychedelic & Consciousness Research has openings in their upcoming study: Psilocybin as a Potential Aid for Post Treatment Lyme Disease for Lyme disease patients in the Baltimore, MD area.

Psilocybin research is being studied as a potential treatment for many things, including Alzheimer’s, Obsessive Compulsive Disorder, Post-Treatment Lyme disease (also commonly called Chronic Lyme disease), Alcoholism and Depression. In the treatment of Lyme, psilocybin has shown potential in improving symptoms such as fatigue, pain, mood, and overall quality of life.

I am always on the lookout for potential new treatment opportunities to share with you, and if you meet the study requirements I hope that you will give it a shot! 

I know that sometimes considering a treatment that might seem unconventional may give some people pause, but I want to remind everyone that this is how new research is discovered and medical advancements are made. I have written before on the inefficacy of traditional treatments, and woefully inadequate amount of funding and research that is dedicated to Lyme disease. My own journey to healing from chronic Lyme disease and multiple co-infections was anything but traditional. 

We have written before about the health benefits of other mushrooms, such as Reishi, Chaga, Cordycep, and Lion’s Mane, so if you are interested in learning more check those out. And I even share about my own personal experience with psilocybin and how it was a turning point in my own Lyme journey on THIS EPISODE of the Tick Boot Camp podcast.  

For more information about this Johns Hopkins program, visit their website.

Here is some information about their mission and values:

“Our Vision: To advance the scientific understanding of psychedelics and their potential for treating mental health disorders, enhancing well-being, and expanding our understanding of consciousness.

Scientists  today are entering a new era of studying a truly unique class of  pharmacological compounds known as psychedelics. Although research with these compounds was first started in the 1950s and ‘60s, it abruptly ended in the early 1970s in response to unfavorable media coverage, resulting in misperceptions of risk and highly restrictive regulations. 

After a decades-long hiatus, in 2000 our research group at Johns Hopkins was the first to obtain regulatory approval in the United States to reinitiate research with psychedelics in healthy, psychedelic-naive volunteers. Our 2006 publication on the safety and enduring positive effects of a single dose of psilocybin is widely considered the landmark study that sparked a renewal of psychedelic research world-wide.  

Since that time, we have published further groundbreaking studies in more than 150 peer-reviewed articles in respected scientific journals. This makes Johns Hopkins the leading psychedelic research institution in the U.S., and among the few leading groups worldwide. Our research is investigating therapeutic effects in people who suffer a range of challenging conditions including addiction (smoking, alcohol, other drugs of abuse),  existential distress caused by life-threatening disease, major depressive disorder, anorexia nervosa, Post-Treatment Lyme Disease, depression associated with Alzheimer’s Disease, and Obsessive-Compulsive Disorder. Studying healthy volunteers has also advanced our understanding of the enduring positive effects of psilocybin and provided unique insight into neurophysiological mechanisms of action, with implications for understanding consciousness and optimizing therapeutic and non-therapeutic enduring positive effects.”